These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32981389)

  • 1. Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation.
    Cappelli F; Tini G; Russo D; Emdin M; Del Franco A; Vergaro G; Di Bella G; Mazzeo A; Canepa M; Volpe M; Perfetto F; Autore C; Di Mario C; Rapezzi C; Musumeci MB
    Amyloid; 2021 Mar; 28(1):12-18. PubMed ID: 32981389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic embolism in amyloid transthyretin cardiomyopathy.
    Vilches S; Fontana M; Gonzalez-Lopez E; Mitrani L; Saturi G; Renju M; Griffin JM; Caponetti A; Gnanasampanthan S; De Los Santos J; Gagliardi C; Rivas A; Dominguez F; Longhi S; Rapezzi C; Maurer MS; Gillmore J; Garcia-Pavia P
    Eur J Heart Fail; 2022 Aug; 24(8):1387-1396. PubMed ID: 35650018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pacemaker-detected atrial fibrillation burden and risk of ischemic stroke or thromboembolic events-A cohort study.
    Chu SY; Jiang J; Wang YL; Sheng QH; Zhou J; Ding YS
    Heart Lung; 2020; 49(1):66-72. PubMed ID: 31376922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.
    Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
    Europace; 2014 Feb; 16(2):195-201. PubMed ID: 24036378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation in "real world" patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study.
    Volterrani M; Iellamo F; Rosano G; Guarini P; Pusineri E; Bonassi S; Chimini C; Zaccà F; Proto C;
    Int J Cardiol; 2013 Oct; 168(5):4729-33. PubMed ID: 23948115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
    Zhu WG; Xiong QM; Hong K
    Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Oral Anticoagulants in Cardiac Amyloidosis: Lights and Shadows.
    Di Lisi D; Di Caccamo L; Damerino G; Portelli MC; Comparato F; Di Stefano V; Brighina F; Corrado E; Galassi AR; Novo G
    Curr Probl Cardiol; 2023 Aug; 48(8):101188. PubMed ID: 35346721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The thromboembolism risk of low-risk atrial fibrillation patients with different clinical characteristics].
    Liu XB; Jia ZX; Xia SJ; He L; Lu SX; Guo XY; Li SN; Liu N; Jiang CX; Sang CH; Tang RB; Long DY; Yu RH; Bai R; Wu JH; Du X; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):735-739. PubMed ID: 32957755
    [No Abstract]   [Full Text] [Related]  

  • 9. Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE.
    Goto S; Merrill P; Wallentin L; Wojdyla DM; Hanna M; Avezum A; Easton JD; Harjola VP; Huber K; Lewis BS; Parkhomenko A; Zhu J; Granger CB; Lopes RD; Alexander JH
    Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):75-81. PubMed ID: 29385429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
    Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Angoulvant D; Babuty D; Lip GY; Fauchier L
    Thromb Haemost; 2016 May; 115(5):1056-63. PubMed ID: 26843425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology, Mechanisms, and Management of Atrial Fibrillation in Cardiac Amyloidosis.
    Bukhari S; Oliveros E; Parekh H; Farmakis D
    Curr Probl Cardiol; 2023 Apr; 48(4):101571. PubMed ID: 36584731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
    Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
    Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
    Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of insertable cardiac monitors in anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding.
    Mascarenhas DA; Farooq MU; Ziegler PD; Kantharia BK
    Europace; 2016 Jun; 18(6):799-806. PubMed ID: 26614520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Thromboembolism in Non-Valvular Atrial Fibrillation With or Without Clinical Hyperthyroidism.
    Lin YS; Tsai HY; Lin CY; Wu VC; Chen TH; Yang TY; Aboyans V; Chen MC
    Glob Heart; 2021 Jun; 16(1):45. PubMed ID: 34211831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with atrial fibrillation and mid-range ejection fraction differ in anticoagulation pattern, thrombotic and mortality risk independently of CHA
    Jurin I; Lucijanic M; Jurin H; Starcevic B; Varvodic J; Catic J; Jurisic A; Vitlov P; Sokol Tomic S; Lucijanic J; Hadzibegovic I
    Heart Vessels; 2020 Sep; 35(9):1243-1249. PubMed ID: 32248252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Young Male Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study.
    Chan YH; Wu LS; Chang SH; Lee HF; Liu JR; See LC; Yeh YH; Kuo CT
    PLoS One; 2016; 11(3):e0151485. PubMed ID: 26986069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.